Evotec SE

Evotec SE discloses voting‑rights filings, CEO’s marathon restructuring remarks, JPMorgan stake cut, and shares hit a 52‑week high—an in‑depth look at the company’s governance and market impact.

Evotec SE, a German life sciences services provider, is navigating a new era of AI-driven drug discovery amidst market volatility, with its share price influenced by regulatory scrutiny of short-selling practices and the potential for undervaluation…

Evotec SE and Sandoz AG have announced a non-binding agreement for the potential sale of Evotec’s Toulouse biologics facility to Sandoz for approximately $300 million.

Evotec SE receives $2.5 million grant from the Gates Foundation to develop new tuberculosis treatment regimens, but its stock price drops amid concerns over its financial stability.

Evotec SE has received a $2.5 million grant from the Bill & Melinda Gates Foundation to develop next-generation tuberculosis treatments, despite facing financial challenges and a recent stock price decline.